Get the Stockscreener App
125.21
15.38%
16.69
Pre-market:
124.50
-0.71
-0.57%
Grail Inc stock is traded at $125.21, with a volume of 3.44M.
It is up +15.38% in the last 24 hours and up +63.50% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$108.52
Open:
$105.5
24h Volume:
3.44M
Relative Volume:
4.12
Market Cap:
$5.59B
Revenue:
$156.12M
Net Income/Loss:
$-395.33M
P/E Ratio:
-12.07
EPS:
-10.3758
Net Cash Flow:
$-292.33M
1W Performance:
+56.61%
1M Performance:
+63.50%
6M Performance:
+157.37%
1Y Performance:
+168.81%
1-Day Range:
$101.98
$126.81
1-Week Range:
$78.20
$126.81
52-Week Range:
$41.50
$126.81
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
125.21 | 5.59B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Mizuho | Neutral |
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
GRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focus - Stocktwits
Grail multicancer detection test wins FDA advisers’ backing - BioPharma Dive
This Controversial Cancer Test Just Passed a Key FDA Vote. Here's Why It's Dividing Experts - inc.com
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued? - finance.yahoo.com
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test - Investor's Business Daily
FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says - LiveNOW from FOX
GRAL Stock Surges As Traders Target High-Momentum Breakout - timothysykes.com
GRAL Stock Rockets As Traders Chase Breakout Momentum - StocksToTrade
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool - Benzinga
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test - marketscreener.com
Grail stock hits all-time high at 119.09 USD - Investing.com
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply. - Barron's
Grail stock hits all-time high at 119.09 USD By Investing.com - Investing.com Canada
Canaccord reiterates Buy on Grail stock after FDA panel vote - Investing.com
What is next for Grail stock after surging on positive FDA comments? - Investing.com
FDA panel endorses first-of-a-kind cancer blood test from Grail - Daily Herald
Grail survives adcomm vote as it awaits FDA decision for cancer blood test - Fierce Biotech
FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test - allsci.com
Grail MCED Test is Safe, Effective, Experts Tell FDA, While Questioning ‘Early Detection’ Claim - GenomeWeb
FDA panel endorses GRAIL’s multi-cancer early detection test - Yahoo
Premarket movers: Stitch Fix tumbles, Grail surges - Investing.com
Why is Grail stock surging today? - Investing.com
FDA panel backs Galleri blood test that screens for more than 50 cancers - Straight Arrow
Canaccord reiterates Buy on Grail stock after FDA panel vote By Investing.com - Investing.com Canada
FDA panel endorses blood cancer test from Grail - wsbtv.com
One blood test could screen you for 50 cancers. Here’s why it’s controversial. - The Washington Post
New blood test can detect more than 50 types of cancer. Here’s what to know - WEAU
FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks - STAT
Grail's cancer blood test faces high-stakes FDA review - Bedford Gazette
Grail cancer test gets lukewarm backing from FDA adcomm - pharmaphorum
Why Is Grail (NASDAQ:GRAL) Moving Into Focus? - Kalkine Media
How Investors May Respond To GRAIL (GRAL) Favorable FDA Panel Vote - simplywall.st
Grail's cancer blood test faces FDA review - timesdaily.com
FDA panel backs efficacy of Grail's cancer test in tight vote - FirstWord
A Single Blood Draw Screens 50+ Cancers: FDA Panel Endorsement Pushes GRAIL's Test Toward a New Era - finance.biggo.com
GRAIL's Galleri test wins endorsement from FDA panel - TradingView
Grail’s cancer-screen blood test wins tepid support from US drug advisory panel - Financial Times
US FDA advisers endorse Grail cancer test's benefits in key vote - Reuters
FDA panel votes 6-4 for Grail Galleri efficacy in cancer screening - scanx.trade
Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval - WSJ
F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test - The New York Times
The Holy Grail In Cancer? FDA Panel Backs Blood Tests. - Investor's Business Daily
FDA panel endorses first-of-a-kind cancer blood test from Grail | National News | 2news.com - KTVN
Grail’s Blood Test to Detect Multiple Cancers Wins FDA Panel Backing - Bloomberg
FDA panel endorses first-of-a-kind cancer blood test - NBC 5 Chicago
GRAIL, Inc. (GRAL) Wins Favorable FDA Panel Vote on Galleri PMA - TradingView
Grail’s cancer blood test faces high-stakes FDA review - Chicago Tribune
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy - marketscreener.com
At prices up to $95 a share, GRAIL (GRAL) CFO Aaron Freidin sold 4,100 shares under a trading plan. - Stock Titan
Advisers set to vote on Grail’s cancer blood test during high-stakes FDA review - aol.com
Cancer Test - Washington Times
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):